Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc.ELDN · Entity 6160 | Director | January 10, 2026 | January 16, 2026 |
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eledon Pharmaceuticals, Inc.
Report date January 10, 2026 · Filed January 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,430 |
Reported balance
After 2026-01-10 transaction · row 1
1 source rowRow 1 · 2026-01-10 · Exercise / conversion · Acquired 3,430 · Balance 3,430 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-10 · Exercise / conversion · Disposed 3,430 · Balance 0 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.
Tenaya Therapeutics, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2036-05-27 | Direct | 120,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 120,000 · Balance 120,000 F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CinCor Pharma, Inc.
Report date February 24, 2023 · Filed February 24, 2023
Section 16 reporting ended · disclosed 2023-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2032-01-10 | Direct | 0 |
Reported balance
After 2023-02-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-24 · Disposition to issuer · Disposed 47,954 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033.
MyoKardia, Inc.
Report date May 02, 2018 · Filed October 29, 2019
Section 16 reporting ended · disclosed 2019-10-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,157 |
Ending reported balance
After 2019-02-25 transaction · row 11
11 source rows · reconciled sequenceRow 1 · 2018-05-02 · Exercise / conversion · Acquired 5,457 · Balance 9,610 Row 2 · 2018-05-09 · Exercise / conversion · Acquired 4,500 · Balance 14,110 Row 3 · 2018-05-31 · Exercise / conversion · Acquired 364 · Balance 14,474 Row 4 · 2018-07-10 · Exercise / conversion · Acquired 364 · Balance 14,838 Row 5 · 2018-08-09 · Exercise / conversion · Acquired 363 · Balance 15,201 Row 6 · 2018-09-04 · Exercise / conversion · Acquired 364 · Balance 15,565 Row 7 · 2018-10-01 · Exercise / conversion · Acquired 364 · Balance 15,929 Row 8 · 2018-10-11 · Exercise / conversion · Acquired 2,500 · Balance 18,429 Row 9 · 2018-11-06 · Exercise / conversion · Acquired 364 · Balance 18,793 Row 10 · 2018-12-03 · Exercise / conversion · Acquired 364 · Balance 19,157 Row 11 · 2019-02-25 · Exercise / conversion · Acquired 3,000 · Balance 22,157 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 110,160 |
Reported balance
After 2018-05-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-05-02 · Exercise / conversion · Disposed 5,457 · Balance 110,160 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 105,660 |
Reported balance
After 2018-05-09 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2018-05-09 · Exercise / conversion · Disposed 4,500 · Balance 105,660 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 105,296 |
Reported balance
After 2018-05-31 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2018-05-31 · Exercise / conversion · Disposed 364 · Balance 105,296 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 104,932 |
Reported balance
After 2018-07-10 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2018-07-10 · Exercise / conversion · Disposed 364 · Balance 104,932 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 104,569 |
Reported balance
After 2018-08-09 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2018-08-09 · Exercise / conversion · Disposed 363 · Balance 104,569 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 104,205 |
Reported balance
After 2018-09-04 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2018-09-04 · Exercise / conversion · Disposed 364 · Balance 104,205 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 103,841 |
Reported balance
After 2018-10-01 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2018-10-01 · Exercise / conversion · Disposed 364 · Balance 103,841 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 101,341 |
Reported balance
After 2018-10-11 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2018-10-11 · Exercise / conversion · Disposed 2,500 · Balance 101,341 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 100,977 |
Reported balance
After 2018-11-06 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2018-11-06 · Exercise / conversion · Disposed 364 · Balance 100,977 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 100,613 |
Reported balance
After 2018-12-03 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2018-12-03 · Exercise / conversion · Disposed 364 · Balance 100,613 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 3,250 |
Reported balance
After 2019-02-25 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2019-02-25 · Exercise / conversion · Disposed 3,000 · Balance 3,250 F2: On February 1, 2017, the Reporting Person was granted an option to purchase 25,000 shares of Common Stock under the issuer's 2015 Equity Incentive Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the issuer's securities. On June 28, 2018, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 6,250 of the shares underlying such option. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
F2: On February 1, 2017, the Reporting Person was granted an option to purchase 25,000 shares of Common Stock under the issuer's 2015 Equity Incentive Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the issuer's securities. On June 28, 2018, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 6,250 of the shares underlying such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 364 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · derivative · entry 18 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,841 Underlying: Common Stock · 364 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| October 01, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 364 | $11.95 | $4,349.80 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · nonDerivative · entry 7 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 20:26 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-18-025124 · doc4.xml · derivative · entry 4 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 20:26 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 908 | $63.84 | $57,963.00 |
DisclosureSEC source: 0000899243-18-025124 · doc4.xml · nonDerivative · entry 3 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $63.45 to $64.35 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 20:26 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 4,092 | $62.97 | $257,689.20 |
DisclosureSEC source: 0000899243-18-025124 · doc4.xml · nonDerivative · entry 2 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,334 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $62.40 to $63.30 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 20:26 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 5,000 | $11.95 | $59,750.00 |
DisclosureSEC source: 0000899243-18-025124 · doc4.xml · nonDerivative · entry 1 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 04, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 364 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · derivative · entry 17 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,205 Underlying: Common Stock · 364 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| September 04, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 364 | $11.95 | $4,349.80 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · nonDerivative · entry 6 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 363 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · derivative · entry 16 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,569 Underlying: Common Stock · 363 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| August 09, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 363 | $11.95 | $4,337.85 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · nonDerivative · entry 5 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 364 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · derivative · entry 15 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,932 Underlying: Common Stock · 364 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| July 10, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 364 | $11.95 | $4,349.80 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · nonDerivative · entry 4 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 17:45 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-18-018746 · doc4.xml · derivative · entry 1 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2027-01-31 F1 · balance_after: On February 1, 2017, the Reporting Person was granted an option to purchase 25,000 shares of Common Stock under the issuer's 2015 Equity Incentive Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the issuer's securities. On June 28, 2018, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 6,250 of the shares underlying such option. Read SEC document |
| May 31, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 364 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · derivative · entry 14 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,296 Underlying: Common Stock · 364 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 31, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 364 | $11.95 | $4,349.80 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · nonDerivative · entry 3 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · derivative · entry 13 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,660 Underlying: Common Stock · 4,500 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 09, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 4,500 | $11.95 | $53,775.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · nonDerivative · entry 2 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,457 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · derivative · entry 12 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,160 Underlying: Common Stock · 5,457 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 02, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 5,457 | $11.95 | $65,211.15 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · nonDerivative · entry 1 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2018 Filed Jun 1, 2018 16:25 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantCommon Stock | 426 | $33.15 | $14,121.90 |
DisclosureSEC source: 0000899243-18-014679 · doc4.xml · nonDerivative · entry 1 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 19:59 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantRestricted Stock Units · Derivative | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001389 · doc4.xml · derivative · entry 2 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 19:59 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 66,400 | $0.00 Strike: $52.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001389 · doc4.xml · derivative · entry 1 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,400 Underlying: Common Stock · 66,400 shares Expires 2028-01-15 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2018, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| February 01, 2017 Filed Feb 1, 2017 18:53 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-17-002398 · doc4.xml · derivative · entry 1 Lee June · CIK 0001696493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-01-31 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 31, 2018, and the remaining shares subject to this option shall vest and become exercisable in 36 equal monthly installments thereafter. This option is subject to full acceleration of vesting with respect to all then-unvested shares in the event the reporting person's service relationship is terminated by the issuer or any successor without Cause (as defined in the issuer's 2015 Stock Option and Incentive Plan) within one year following the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.